Research
Hormonal
Glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse cardiovascular events (MACE) in patients with overweight, obesity, and established cardiovascular disease (CVD) with and without diabetes.
Practitioners can consider glucagon-like peptide 1 receptor agonists as effective treatments for reducing cardiovascular events in eligible patients.
StrongSupportsmedium confidence
Across large CV outcome trials, glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse CV events (MACE) in patients with overweight, obesity and established CVD with and without diabetes.
Why this rating
Based on large cardiovascular outcome trials mentioned in the abstract.
Source
Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery
Itxaso K Villelabeitia et al. · Heart · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →